Previous post Next post

Novartis launches direct sales platform in US in bid to lower drug prices

Novartis is starting a new chapter in US sales: On Monday, the pharmaceutical company announced that it will sell its psoriasis drug Cosentyx (secukinumab) directly to cash-paying patients in the US via a direct-to-patient (DTP) platform. +Get the most important news from Switzerland in your inbox This platform is set to launch on November 1, 2025. It will offer patients who have been prescribed the drug the opportunity to purchase it at a 55% discount on the list price. According to the press release, Cosentyx is Novartis’ best-selling product in the US. It is a biologic approved for the treatment of various immune-mediated inflammatory diseases. “In the US, we have long recognised that we need new ways to reach patients more directly by removing barriers in the system,” Victor Bultó, President of Novartis in the US, is quoted as saying in the announcement. The launch of this new platform is a first step, and Novartis is looking to apply this offering to other drugs as well. Full story here Are you the author?
About Swissinfo
Swissinfo
SWI swissinfo.ch – the international service of the Swiss Broadcasting Corporation (SBC). Since 1999, swissinfo.ch has fulfilled the federal government’s mandate to distribute information about Switzerland internationally, supplementing the online offerings of the radio and television stations of the SBC. Today, the international service is directed above all at an international audience interested in Switzerland, as well as at Swiss citizens living abroad.
Previous post See more for 3.) Swissinfo Business and Economy Next post
Tags: ,

Permanent link to this article: https://snbchf.com/2025/09/novartis-launches-sales-platform-lower-drug-prices/

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

This site uses Akismet to reduce spam. Learn how your comment data is processed.